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In searching for a putative third gene for autosomal dominant polycystic kidney disease (ADPKD), we studied the
genetic inheritance of a large family (NFL10) previously excluded from linkage to both the PKD1 locus and the
PKD2 locus. We screened 48 members of the NFL10 pedigree, by ultrasonography, and genotyped them, with
informative markers, at both the PKD1 locus and the PKD2 locus. Twenty-eight of 48 individuals assessed were
affected with ADPKD. Inspection of the haplotypes of these individuals suggested the possibility of bilineal disease
from independently segregating PKD1 and PKD2 mutations. Using single-stranded conformational analysis, we
screened for and found a PKD2 mutation (i.e., 2152delA; L736X) in 12 affected pedigree members. Additionally,
when the disease status of these individuals was coded as “unknown” in linkage analysis, we also found, with
markers at the PKD1 locus, significant LOD scores (i.e., 13.0). These findings strongly support the presence of a
PKD1 mutation in 15 other affected pedigree members, who lack the PKD2 mutation. Two additional affected
individuals had trans-heterozygous mutations involving both genes, and they had renal disease that was more severe
than that in affected individuals who had either mutation alone. This is the first documentation of bilineal disease
in ADPKD. In humans, trans-heterozygous mutations involving both PKD1 and PKD2 are not necessarily embry-
onically lethal. However, the disease associated with the presence of both mutations appears to be more severe
than the disease associated with either mutation alone. The presence of bilineal disease as a confounder needs to
be considered seriously in the search for the elusive PKD3 locus.
Introduction
Autosomal dominant polycystic kidney disease
(ADPKD) is a common Mendelian disorder (PKD [MIM
173900]) that affects ∼1/500 live births. Clinically, it is
characterized by progressive formation and enlargement
of renal and extrarenal cysts, typically leading to chronic
renal failure in late middle age. Overall, it accounts for
5%–10% of all cases of end-stage renal disease (Fick
and Gabow 1994; Harris 1999). ADPKD is genetically
heterogeneous. Linkage studies have shown that PKD1
(MIM 601313) on chromosome 16p is responsible for
80%–85% of all cases of ADPKD, whereasPKD2 (MIM
173910) on chromosome 4q is thought to account for
most of the remaining cases (Parfrey et al. 1990; Fick
and Gabow 1994; Harris 1999). Recent documentation
of several families that do not show linkage to either of
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the known loci has led to the suggestion that there is at
least one more locus (PKD3 [MIM 600666]) for
ADPKD (Bogdanova et al. 1995; Daoust et al. 1995; De
Almeida et al. 1995; Turco et al. 1996; Ariza et al. 1997;
Paterson and Pei 1998). In searching for this putative
locus, we studied the genetic inheritance of a large mul-
tigeneration family (NFL10) with ADPKD, which we
previously had excluded from linkage to the known loci.
Further analysis of this pedigree, however, revealed a
complex pattern of inheritance, with bilineal disease aris-
ing from independently segregating PKD1 and PKD2
mutations.
Subjects and Methods
Study Subjects
Part of the NFL10 pedigree, consisting of 16 affected
and 14 unaffected individuals, had been studied previ-
ously and excluded from linkage (i.e., LOD scores
!2.0) to either the PKD1 locus or the PKD2 locus
(Parfrey et al. 1990). In the present study, we ascertained
a more complete structure of this pedigree and traced
the genealogy over six generations. Forty-four at-risk
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individuals and four spouses, all of whom gave informed
consent, were studied. The research protocols used for
this study were approved by the Human Subject Review
Committees of both the University of Toronto and Me-
morial University in Newfoundland.
Clinical Outcome
All the at-risk individuals and spouses were screened
with at least one abdominal ultrasound. All the scans were
performed under the supervision of one ultrasonographer
and were interpreted by a radiologist (Dr. Benvon Cramer,
Department of Radiology, Memorial University, St.
John’s, Newfoundland), who had no knowledge of the
clinical status of the subjects. The following criteria were
used for the diagnosis of ADPKD: (i) the presence of at
least two renal cysts (unilateral or bilateral) in an at-risk
individual aged !30 years; (ii) the presence of at least two
cysts in each kidney in an at-risk individual aged 30–59
years; or (iii) the presence of at least four cysts in each
kidney in an at-risk individual aged 60 years (Ravine
et al. 1992). The number of cysts present in the liver was
graded semiquantitatively as (a) !5 (with the actual num-
ber reported); (b) 5–10; and (c) 110. Serum creatinine
was measured with an autoanalyzer. Creatinine clearance,
adjusted for age, gender, and body weight, was calculated
using the formula of Cockcroft and Gault (1976).
Genotyping and Haplotype Construction
We genotyped all the study subjects, with six poly-
morphic simple-sequence repeat (SSR) markers at the
PKD1 locus and five polymorphic SSR markers at the
PKD2 locus. The locations of these markers relative to
thePKD1 locus are as follows (the number between mark-
ers denotes intermarker distance [cM]): D16S521-2.0-
HBAP1-2.0-KG8/PKD1-0.1-D16S665-0.1-D16S291-
0.6-D16S2618 (Germino et al. 1992). KG8 is an
intragenic marker located within the 3′ end of PKD1.
The locations of these markers relative to the PKD2
locus are as follows: D4S231-2.0-D5S1534-2.3-SPP1-
0.2-PKD2-0.5-D4S1563-2.0-D4S423 (San Milla´n et al.
1995). Genotyping was performed by [32P]a-dCTP–
labeling of the PCR products and was analyzed by
PAGE. All genotypings were performed at least twice
and were scored independently by two of us (A.D.P. and
K.R.W.), who had no knowledge of the clinical status
of the study subjects. Any ambiguity in the allele scoring
was resolved by retyping of the marker. Additionally, all
intermarker recombinants were restudied and confirmed
by repeated DNA sampling and genotyping. Haplotypes
were constructed using the program SIMWALK 2 (Sobel
and Lange 1996).
PKD2 Mutation Analysis
In two selected individuals (OP120 and OP14), we
screened for mutations in the entire PKD2 coding se-
quence, by single-stranded conformational analysis
(SSCA). All 15 exons, including their splice junctions,
were amplified from genomic DNA and were screened
at three or more different temperatures, through use of
a thermoflow electrophoresis temperature control sys-
tem (Novex). All PCR products were separated by elec-
trophoresis on a 20% polyacrylamide gel and were
visualized by silver staining (Pei et al. 1998). An SSCA
variant was identified in exon 11 of individual OP120.
To define this mutation, both strands of the PCR frag-
ment were sequenced directly through use of the fluo-
rescent dideoxy terminator method and were analyzed
with an ABI 373 DNA sequencer (PE Biosystems). Allele-
specific oligonucleotide (ASO) hybridization was per-
formed to analyze the segregation of this mutation
(2152delA) in other members of the pedigree. Two oli-
gonucleotide probes (wild-type [WT], 5′-CTGAAAAAA-
AATACCGTG-3′; and mutant [MT], 5′-AACTGAAAA-
AAATACCGTG-3′) were used for the analysis (Pei et al.
1998).
PKD1 Linkage Studies
Two-point linkage analysis using the “affected-only
analysis” subroutine was performed using the MLINK
program of the FASTLINK package, version 4.0 (La-
throp and Lalouel 1984; Terwilliger and Ott 1994). An
autosomal dominant model from a single locus with a
disease-allele frequency of .001 and a phenocopy rate
of .001 was assumed. The disease status of all individuals
with the PKD2 mutation (2152delA) and of individual
OP14 was coded as unknown. Marker-allele frequencies
were obtained from married-in individuals and from re-
construction of the founder genotypes. All inbreeding
loops were broken.
Results
Genealogy and Clinical Ascertainment
On the basis of the genotype data for 16 affected and
14 unaffected individuals, and assuming an autosomal
dominant model from a single disease locus, we previ-
ously had excluded NFL10 from linkage to either the
PKD1 locus or the PKD2 locus (data not shown) (Par-
frey et al. 1990). In the present study, we extended the
genealogy of NFL10 to construct a more complete ped-
igree structure. Further ascertainment revealed a large
and complex pedigree consisting of130 members over
six generations. Additionally, we identified three previ-
ously unknown consanguineous relationships (i.e., be-
tween individuals OP9 and OP10, between individuals
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OP11 and OP12, and between individuals OP125 and
OP140) and two additional branches of the family (rep-
resented by individuals numbered “OP100”–”OP111”
and “OP120”–”OP131”). Figure 1 shows a simplified
and updated pedigree depicting the relationships of sev-
eral key founders and of the 48 members who partici-
pated in the present study. The polycystic kidney disease
in individual OP150 was documented, during abdomi-
nal surgery, as an incidental finding. The diagnosis of
all other affected individuals was confirmed by ultra-
sonography. The diagnoses of individuals OP29 and
OP45, who each have only one renal cyst, at ages 27
years and 37 years, respectively, were considered inde-
terminate.
Genetic Analysis
Haplotype construction was performed at both the
PKD1 locus and the PKD2 locus. Four intermarker re-
combinants were identified at the PKD1 locus (in in-
dividuals OP8, OP10, OP14, and OP111), and three
were identified at the PKD2 locus (in individuals OP13,
OP36, and OP124) (data not shown). Consistent with
our previous linkage results, no single haplotype at either
locus segregated with the disease. Furthermore, no com-
bination of two different haplotypes at either locus could
explain the disease-segregation pattern. These latter ob-
servations provided strong evidence against bilineal dis-
ease from homozygous or compound heterozygous mu-
tations at a single PKD locus. However, we did find that
the combination of the PKD1 haplotype 3-4-1-7-8-5 and
the PKD2 haplotype 2-4-6-6-9 accounted for the disease
in all the affected individuals except OP14. This finding
strongly suggests the possibility of bilineal disease from
trans-heterozygous mutations of both PKD1 and PKD2.
Individual OP14, who had two renal cysts at age 22
years, was considered to be affected with ADPKD. Her
father, who had died at age 57 of renal-cell carcinoma,
did not have renal cysts on autopsy.
To further address the possibility of bilineal disease in
this pedigree, we screened individual OP120, whose dis-
ease cosegregated with the PKD2 haplotype 2-4-6-6-9,
for PKD2 mutations. We found a frameshift mutation
(2152delA; L736X) on exon 11 in this individual (fig.
2a). ASO hybridization analysis further showed cose-
gregation of this mutation with only the affected indi-
viduals with the PKD2 haplotype 2-4-6-6-9 and with
none of the unaffected individuals (figs. 1 and 2b). We
screened individual OP14 for PKD2 mutations but did
not find any SSCA variant. The disease in this individual
was not explained by our haplotype analysis.
We also sought evidence for an additional PKD1 mu-
tation in the other affected members who lack the PKD2
mutation. When the disease status of all the individuals
with the PKD2 mutation and of individual OP14 was
coded as unknown in linkage analysis, we found sig-
nificant LOD scores (i.e., 13.0) in 4/6 informative mark-
ers at the PKD1 locus. KG8, which is an intragenic
marker of PKD1, yielded a LOD score of 5.0 at vp
. These findings strongly support the presence of an.00
independently segregating PKD1 mutation in the 15
other affected members, who lack the PKD2 mutation
(table 1). Two additional affected individuals (i.e., OP8
and OP13) were found to have the PKD1 disease hap-
lotype (i.e., 3-4-1-7-8-5) and the PKD2 mutation.
Genotype-Phenotype Correlation
Figure 3 shows the distribution of creatinine clearances
in all the affected individuals, by their age at their last
serum creatinine measurement; prior to the creatinine
measurement, none had either any concomitant renal dis-
ease or a nephrectomy. In this family, it is evident that
the age-adjusted disease severity associated with the
PKD1 germline mutation is similar to that associated with
the PKD2 mutation. At the last follow-up, four affected
individuals (i.e., OP8, OP13, OP120, and OP127) were
diagnosed as having end-stage renal disease (ESRD). In-
dividuals OP8 and OP13, who had trans-heterozygous
mutations of both PKD1 and PKD2, developed ESRD at
ages 48 years and 52 years, respectively. In contrast, in-
dividuals OP120 and OP127, who carried only the PKD2
mutation, developed ESRD at ages 69 years and 68 years,
respectively. Additionally, at similar ages, the creatinine
clearance of individuals OP8 and OP13 was severely re-
duced when compared with that of OP103 and OP107,
who had only the PKD1 mutation (10 ml/min/1.73m2 vs.
80 and 86 ml/min/1.73 m2, respectively; normal reference
range 95–130 ml/min/1.73 m2). Thus, the renal disease
in individuals with the trans-heterozygous mutations was
more severe than that in the other affected family mem-
bers, who had either the PKD1 mutation or the PKD2
mutation alone.
The liver is the second-most-common organ to un-
dergo cystic changes in ADPKD. When a semiquanti-
tative scoring system for number of cysts was used, in-
dividuals OP8 and OP13 appeared to have more liver
cysts than did the other affected family members, who
had either the PKD1 mutation or the PKD2 mutation
alone (table 2). However, neither OP8 nor OP13 had
massive polycystic liver resulting in either portal hyper-
tension or hepatic failure. Moreover, cystic liver disease
in females with ADPKD tends to be more severe than
in males with ADPKD (Chauveau et al. 1997). Thus, we
could not conclude definitively that the cystic liver dis-
ease in trans-heterozygous individuals was more severe
than that in other affected members, who had the PKD1
mutation or the PKD2 mutation alone. None of the
affected members of NFL10 had a history of intracranial
arterial aneurysms.
Figure 1 Simplified pedigree structure of NFL10, and haplotype analysis at the PKD1 and PKD2 loci. In the present study, we have identified three previously unknown consanguineous
relationships (between individuals OP9 and OP10, between OP11 and OP12, and between OP125 and OP140; denoted by double lines between the individuals) and two additional branches of the
family (represented by individuals numbered “OP100”–”OP111” and “OP120”–”OP131”). The combination of the PKD1 haplotype 3-4-1-7-8-5 (blue bar) and the PKD2 haplotype 2-4-6-6-9 (red
bar) accounted for the disease in all affected individuals except OP14; OP14, who had two renal cysts at age 22 years, was considered to be affected with ADPKD. These findings suggest the possibility
of bilineal disease from independently segregating PKD1 and PKD2 mutations. Individuals with indeterminate disease status are denoted by the half-blackened symbols. The age at the last ultrasound
test is shown in parentheses. All individuals with the slanted-T symbols have been genotyped.
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Figure 2 PKD2 mutation analysis in NFL10. a, Sequence trac-
ings of exon 11 PCR products from a control subject (top panel) and
individual OP120 (bottom panel). A heterozygous PKD2 frameshift
mutation (i.e., 2152delA) is detected in OP120. This mutation is ex-
pected to truncate the mutant protein product at codon 736 (i.e.,
L736X). b, Representative data from ASO hybridization analysis. Cos-
egregation of the mutation depicted in panel a occurs only with the
affected individuals with the PKD2 haplotype 2-4-6-6-9 and not with
the unaffected individuals.
Table 1
Two-Point Linkage Analysis Data at the PKD1 Locus (Affected-
Only Analysis)
MARKER
LOD SCORE AT v p
.00 .01 .05 .10 .20 .30 .40
D16S521 2.90 2.83 2.57 2.24 1.58 .95 .40
HBAP1 2.69 2.63 2.40 2.11 1.53 .97 .46
KG8 5.03 4.94 4.57 4.10 3.10 2.03 .94
D16S655 4.25 4.17 3.85 3.43 2.56 1.64 .72
D16S291 4.25 4.17 3.85 3.43 2.57 1.67 .76
D16S2618 3.54 3.49 3.26 2.94 2.21 1.40 .59
NOTE.—Marker-allele frequencies estimated from founders and
married-in subjects. The disease-segregation pattern with the
PKD1 haplotype 3-4-1-7-8-5 (see fig. 1) is consistent with the
LOD-score results.
Discussion
In searching for a putative novel locus for ADPKD, we
unraveled the complex inheritance of a large, multige-
neration family. Careful analysis of the NFL10 pedigree
suggested the possibility of two independently segregat-
ing PKD1 and PKD2 mutations. The combination of
the PKD1 haplotype 3-4-1-7-8-5 and the PKD2 hap-
lotype 2-4-6-6-9 accounted for 27/28 definitively af-
fected individuals, and neither haplotype was present in
any clearly unaffected individuals (fig. 1). The disease in
individual OP14, who carried neither of the aforemen-
tioned haplotypes but who had two renal cysts at age
22 years, remains unexplained. It is possible that she
may represent a phenocopy, since simple renal cysts can
occur in the normal population, albeit rarely in people
!30 years of age (Laucks and McLachlan 1981; Tada
et al. 1983). Alternatively, her disease could be due to
a de novo mutation in PKD1.
To further address the possibility of bilineal disease
in this pedigree, we screened for and found a frameshift
PKD2 mutation in individual OP120. ASO hybridiza-
tion analysis showed that this mutation cosegregated
with the PKD2 haplotype 2-4-6-6-9 and that it ap-
peared to have originated from two founders, OP150
and OP155, in the third generation (fig. 1). This finding
thus provided definitive proof for at least two indepen-
dently segregating mutations in this family. Presently,
mutation screening of PKD1 remains a challenge be-
cause of both its size (i.e., there is a ∼13-kb open reading
frame within its mRNA transcript) and its complexity
(i.e., ∼75% of the gene is duplicated in at least three
homologous genes, and the GC content is ∼65%) (Peral
et al. 1996, 1997; Thomas et al. 1999; Watnick et al.
1999). Therefore, we did not attempt to prove the pres-
ence of a PKD1 disease allele by direct mutation screen-
ing. Instead, using linkage analysis, we found strong
evidence supporting the presence of an additionalPKD1
mutation in 15 other affected members, who lack the
PKD2 mutation (table 1 and fig. 1). Although the actual
PKD1 mutation in this family is presently unknown, it
appears to have originated from two founders, OP152
and OP154. The marriage of individuals OP154 and
OP155, in turn, introduced both the PKD1 mutation
and the PKD2 mutation into the core family (fig. 1).
Interestingly, in this pedigree, the renal disease severity
in the individuals with the PKD1 haplotype is very sim-
ilar to that in individuals with the PKD2 mutation.
Although the renal disease is generally more severe in
type 1 ADPKD than in type 2 ADPKD, there is a spec-
trum of phenotypic variability, and families with mild
disease have been documented as having ADPKD type
1 (Hateboer et al. 1999). The basis for the interfamilial
phenotypic variability in ADPKD is presently unknown,
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Figure 3 Genotype-phenotype correlation in NFL10. Age-ad-
justed creatinine clearances are plotted against individuals with a mu-
tation in either PKD1 (blue symbol), PKD2 (red symbol), or both
mutations (green symbol). The renal-disease severity is similar in in-
dividuals with either the PKD1 or PKD2 mutation but is more severe
in the two individuals (i.e., OP8 and OP13) with the compound het-
erozygous mutations. The normal reference range is 95–130 ml/min/
1.73 m2.
Table 2
Comparison of Liver Cystic Disease in NFL10
Patienta
Age at Time of
Ultrasound
(years) No. of Liver Cysts
OP100 59 3
OP108 55 2
OP107 52 1
OP103 50 0
OP8a 48 110
OP12a 57 110
OP13a 52 110
OP3a 46 5–10
OP127a 68 5–10
OP120 69 0
OP121 64 0
OP124 59 0
a Ultrasonographic film records were not available for
the more precise estimation of cyst number.
but it has been attributed to genetic and/or environ-
mental factors (Peral et al. 1996; Hateboer et al.1999).
Alternatively, this variability could be due to an allele-
specific effect (Watnick et al. 1999).
Given that ADPKD affects 1 in 500–1,000 live births,
bilineal disease is predicted to occur in ∼1 in
250,000–1,000,000 marriages in the general population
(Paterson and Pei 1998). Two scenarios may result.
First, in families in which the germline mutations in-
volve both copies of either PKD1 or PKD2, homozy-
gous or compound-heterozygous mutations in one of
these genes are expected in 25% of the offspring; sec-
ond, in families in which the germline mutations involve
one copy each of PKD1 and PKD2, trans-heterozygous
mutations in both genes are expected in 25% of the
offspring. Despite these predictions, however, no defin-
itive case of bilineal ADPKD had been documented
prior to the present study. This raises the possibility that
these mutation combinations may be lethal in humans
(Wilkie 1994). Indeed, recent studies of both PKD1-
and PKD2- “knockout” mice support this contention
(Lu et al. 1997, 1999; Wu et al. 1998, 2000). Mice with
heterozygous inactivation of either PKD1 or PKD2 de-
velop focal cysts later in life. In contrast, mice with
homozygous inactivation of either PKD1 or PKD2 die,
either in utero or perinatally, with massive polycystic
kidneys (Lu et al. 1997, 1999; Wu et al. 1998, 2000).
Our documentation of two individuals with trans-het-
erozygous mutations of PKD1 and PKD2 suggests that
this mutation combination is not necessarily lethal.
At least two potential mechanisms may explain the
increased disease severity in the individuals with the
trans-heterozygous mutations, and they need not be mu-
tually exclusive. First, recent human and knockout-
mouse studies have shown that ADPKD is a clonal dis-
order of epithelial cell growth, triggered by somatic
mutagenic events. Specifically, inactivation of both cop-
ies of either PKD1 or PKD2, through germline and
somatic mutations within an epithelial cell, confers
growth advantages for it to expand into a cyst (Qian
et al. 1996; Brasier and Henske 1997; Lu et al. 1997,
1999; Wu et al. 1998, 2000; Koptides et al. 1999; Pei
et al. 1999; Torra et al. 1999). This mechanism for cyst
formation is analogous to Knudson’s “two-hit” model
of carcinogenesis (Reeders 1992). Since the somatic
polycystic kidney disease mutations constitute the rate-
limiting step for individual cyst formation, the fre-
quency of such mutations is predicted to determine both
the number of cysts eventually formed and the disease
severity (Pei et al. 1999). In the individuals with the
trans-heterozygous mutations, all cells have already suf-
fered a “first hit” in both PKD1 and PKD2. The in-
creased disease severity may simply reflect the fact that
all the cells in these individuals have two loci that could
be involved in the somatic “second hits.”
The second mechanism involves a “threshold” effect
(Wilkie 1994). Digenic mutations have been docu-
mented in several Mendelian diseases, including retinitis
pigmentosa (involving RDS and ROM1), Waardenburg
syndrome (involving MITF and TYR), and junctional
epidemolysis bullosa (involving COL17A1 and
LAMB3) (Kajiwara et al. 1994; Morrell et al. 1997;
Floeth and Bruckner-Tuderman 1999). In these dis-
orders, individuals with heterozygous mutations of both
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genes were affected, whereas other family members,
who had heterozygous mutations involving one of the
two genes, were phenotypically normal. A threshold
model has been proposed as the pathophysiological
mechanism for these disorders, since in each case the
disease results from the interactions of two mutant pro-
teins that are components of a multimolecular complex
or pathway. Recent studies have suggested that poly-
cystin 1 and 2 (the gene products of PKD1 and PKD2,
respectively) are components of a novel signaling path-
way that is essential for tubulogenesis (Qian et al. 1997;
Tsiokas et al.1997; Harris 1999). Polycystin 1 is thought
to function as a receptor for cell-cell or cell-matrix in-
teractions, whereas polycystin 2 is predicted to form a
subunit of a channel complex. Both proteins, in turn,
have been shown to interact with each other in vitro
(Qian et al. 1997; Tsiokas et al.1997). Although the
composition and stoichiometry of the polycystin sig-
naling pathway remain to be fully elucidated, it is plau-
sible that the interactions of the mutant proteins arising
from the trans-heterozygous PKD1 and PKD2 muta-
tions could lead to a reduction of the functional sig-
naling complex below a “threshold,” which would pre-
dispose more cells to a cystic phenotype. Under this
model, the type of the PKD1 and PKD2 mutations may
be important for determination of the cystogenic thresh-
old. However, additional modulating factors are re-
quired, since only a relatively small fraction of cells in
the trans-heterozygous individuals acquired the cystic
phenotype. It is of interest to note that both germline
PKD1 and somatic PKD2 mutations—as well as the
opposite—have been recently documented in a small
subset (i.e., ∼10 %) of cysts from patients with ADPKD
(Koptides et al. 2000; Watnick et al. 2000). With the
recent availability of knockout-mouse models for PKD1
and PKD2, these two potential mechanisms now can
be tested experimentally by crossing these animals to
generate knockout mice with trans-heterozygous inac-
tivation of PKD1 and PKD2 (S.S., unpublished data).
The recent application of molecular genetic analysis
to clinical medicine has begun to unravel the complexity
of pathogenic mechanisms in human diseases. The pre-
sent study illustrates such complexity in an otherwise
“simple” Mendelian disorder and provides insight into
the genetic basis for intrafamilial disease variability in
ADPKD. Such knowledge has the potential to improve
the prediction of risk in individual patients and to pro-
vide the framework for the development of mechanism-
based therapeutics. Although several families with
ADPKD have now been reported to show no linkage
to either of the known gene loci, the absence of linkage
in these families does not necessarily imply the presence
of another disease locus (Paterson and Pei 1998, 1999).
A number of potential confounders, including genotyp-
ing errors, nonpaternity, misdiagnosis, and bilineal dis-
ease, could lead to false exclusion of linkage and will
need to be vigorously excluded in these families. The
existence of a third locus for ADPKD remains uncertain
at this time.
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